Primary cardiac tumors

Perchinsky, Michael J.; Lichtenstein, Samuel V.; Tyers, G. Frank O.

doi:10.1002/(sici)1097-0142(19970501)79:9<1809::aid-cncr25>3.0.co;2-0

Cited by 127 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This likely reflects the frequent need for palliative debulking in cardiac sarcoma patients coupled with an appreciation that locoregional progression is often the cause of death even among patients presenting with metastatic disease. These observations echo the trend toward aggressive surgical management advocated by several institutions (6, 8-10, 12). …”

Section: Commentsupporting

confidence: 73%

Primary Cardiac Sarcoma

Hamidi

Moody

Weigel

et al. 2010

The Annals of Thoracic Surgery

138

127

View full text Add to dashboard Cite

Background The presentation, management and outcome of patients with primary cardiac sarcomas are not well defined. Furthermore, the role of adjuvant therapy has not been delineated in the management of primary cardiac sarcomas. Methods Patients with primary cardiac sarcoma and non-cardiac sarcoma, diagnosed between 1988 and 2005, were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Clinical characteristics and outcomes of primary cardiac sarcoma were defined and compared to the characteristics of non-cardiac sarcomas. Univariate and multivariate methods were used to identify factors associated with primary cardiac sarcoma survival. Results Compared to non-cardiac sarcomas, primary cardiac sarcomas were found to occur in a younger age group and were more likely to present with advanced disease. Primary cardiac sarcomas were ten times more likely to be vessel-derived (e.g. angiosarcoma), comprising almost half of all cases. Median overall survival for cardiac sarcoma patients was 6 months while that of non-cardiac sarcoma patients was significantly longer at 93 months (p < .001). Furthermore, cardiac sarcoma patients who underwent surgery had a median survival of 12 months while those who did not undergo surgery had a median survival of one month (p < .001). Conclusions Cardiac sarcomas are a distinct, rare subset of soft tissue sarcomas with a very poor prognosis. Surgery continues to be the central component of successful management. Future clinical efforts should be directed at developing approaches to permit safe radical excision and, potentially, developing effective adjuvant therapy.

show abstract

Section: Commentsupporting

confidence: 73%

Primary Cardiac Sarcoma

Hamidi

Moody

Weigel

et al. 2010

The Annals of Thoracic Surgery

138

127

View full text Add to dashboard Cite

show abstract

“…4,5 The remaining 20% are malignant primary cardiac tumors, of which cardiac sarcomas are the most common. 4,5 However, in our series the most common primary cardiac tumor was malignant cardiac sarcoma. Our institution is a tertiary referral center for malignant disorders and this probably explains this population bias of predominance of malignant over benign cardiac tumors.…”

Section: Discussionmentioning

confidence: 99%

Cardiac Tumors in a Tertiary Care Cancer Hospital: Clinical Features, Echocardiographic Findings, Treatment and Outcomes

Yusuf

Bathina

Qureshi

et al. 2012

Heart International

View full text Add to dashboard Cite

Cardiac tumors are a rare entity, comprised of tumors with diverse histology and natural history. We report the clinical characteristics, echocardiograhic findings, therapy and outcome of 59 patients with primary and metastatic cardiac tumors. Our institutional echocardiogram data base from 1993 through 2005 was reviewed to identify patients diagnosed with intra-cardiac tumor. A total of 59 patients with cardiac tumors were identified and included in the study. The patients' characteristics, presenting symptoms, diagnostic tests, location, histology of the tumor, treatment and the one year survival rate of this population was collected from the medical records. Of the 59 cardiac tumor cases, 16 (27%) were primary cardiac tumors and 43 (73%) were secondary cardiac tumors. The most common primary tumor was sarcoma affecting 13 (81%) of the 16 cases. Of these, 5 patients were angiosarcoma, 5 unclassified sarcoma, one myxoid sarcoma and 2 malignant fibrous histiocytoma. The mean age at presentation was 41.1 years, and the most common location was right atrium affecting 6 cases (37.5%). The most common symptom of dyspnea was present in 10 (62.5%) cases. Eleven (25.6%) of the 43 secondary cardiac tumors were metastasis from renal cell carcinoma. The mean age at presentation was 55.4 years. Right atrium was the most frequent location affecting 18 (42%) of the 43 patients. The most common presenting symptom was dyspnea in 15 (35%) cases. For both primary and secondary tumors, dyspnea was the most common symptom and right atrium was most frequently involved. Sarcoma was the most common primary cardiac tumor while metastasis from renal cell carcinoma was the most common secondary tumor.

show abstract

“…The mean age of patients diagnosed with PMCTs ranged from 35.8 to 68 years of age, and 52.1% of patients were female, according to the available data. For purposes of comparing studies from different periods, we used the median year of each of the following periods when the studies were performed: before 1975 in three data sets [17–19]; between 1975 and 1980 in five data sets [2, 20–23]; between 1981 and 1985 in four data sets [4, 24–26]; between 1986 and 1990 in five data sets [5, 27–30]; between 1991 and 1995 in four data sets [31–34]; between 1996 and 2000 in eight data sets [35–42]; between 2001 and 2005 in six data sets [43–48]; and after 2005 in 3 data sets [16, 49, 50] (Table 1). …”

Section: Resultsmentioning

confidence: 99%

Prevalence of primary cardiac tumor malignancies in retrospective studies over six decades: a systematic review and meta-analysis

Cao

Qin

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The incidence of patients diagnosed with primary malignant cardiac tumors (PMCTs) has increased greatly in the past few decades. Whether this rising prevalence is due to overdiagnosis or an increased malignancy rate of primary cardiac tumors (PCTs) remains unclear. Therefore, we performed a systematic review and meta-analysis of published retrospective studies to determine whether the malignancy rate has been increasing over time. Published studies containing relevant data between 1956 and 2014 were evaluated. Two authors searched for all retrospective studies that included patients diagnosed with PCT and PMCT. Two other investigators independently extracted the data, and discrepancies were resolved by consensus. A random-effects meta-analysis model and cumulative meta-analysis model were used to evaluate the pooled prevalence and trend of dynamic change in PCT malignancies. The effects of time, study period and sample size were studied using a logit-linear regression model with robust error variance and a time variable. Thirty-eight studies involving 5,586 patients were analyzed. The pooled prevalence of PMCT among the patients diagnosed with PCT was 9.9% (95% CI, 8.4% to 11.4%) (I2=70%; P< 0.001), and this prevalence has been stable since around 2003. In the regression model, the malignancy odds ratio remained stable from 1975 onward, and no time effect was observed. Our study confirms that PMCT is uncommon, and the prevalence of PCT malignancies remained stable in the past few decades. The clinically observed increase in incidence is unlikely to reflect a true population-level increase in tumorigenesis. This result strongly suggests that the observed increase in incidence of PMCT most likely reflects increased diagnostic detection over time.

show abstract

Primary cardiac tumors

Cited by 127 publications

References 12 publications

Primary Cardiac Sarcoma

Primary Cardiac Sarcoma

Cardiac Tumors in a Tertiary Care Cancer Hospital: Clinical Features, Echocardiographic Findings, Treatment and Outcomes

Prevalence of primary cardiac tumor malignancies in retrospective studies over six decades: a systematic review and meta-analysis

Contact Info

Product

Resources

About